New York, May 30, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Tumor Infiltrating Lymphocytes Global Market Report 2023" - https://www.reportlinker.com/p06457557/?utm_source=GNW
, Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Seeking Alpha Ltd., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., and Sorrento Therapeutics Inc.
The global tumor infiltrating lymphocytes market is expected to grow from $8.12 billion in 2022 to $9.31 billion in 2023 at a compound annual growth rate (CAGR) of 14.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tumor infiltrating lymphocytes market is expected to grow to $15.56 billion in 2027 at a CAGR of 13.7%.
The tumor infiltrating lymphocytes market consists of sales of autologous TILs (tumor infiltrating lymphocytes), allogeneic TILs, and engineered TILs.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The value of goods in this market includes related services sold by the creators of the goods.
Tumor infiltrating lymphocytes are immune cells that are able to identify and eradicate cancer cells after entering a tumor via the bloodstream. They are extracted from a patient’s tumor, multiplied in large quantities in a lab, and then given back to the person to help the immune system eradicate cancer cells.
North America was the largest region in the tumor infiltrating lymphocytes market in 2022. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main anatomies of tumor-infiltrating lymphocytes include CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, and FOXP3.The cluster of differentiation 3 (CD3) is a multimeric protein complex that was previously known as the T3 complex.
The components include T-cells, B-cells, and natural killer cells for applications in melanoma, cervical cancer, ovarian cancer and others. The end-users include hospitals, cancer research centers, and clinics.
The rising number of cancer patients is expected to propel the growth of the tumor infiltrated lymphocytes (TIL) market going forward.Cancer is a condition in which some cells in the body develop uncontrollably and spread to other regions of the body, leading to a range of health issues, some of which can be fatal.
Tumor-infiltrating lymphocytes are a type of immune cell that can detect and destroy cancer cells.Tumor-infiltrating lymphocytes are extracted from a patient’s tumor and grown externally in massive numbers in a laboratory before being infused back into the patient to assist the immune system in killing the cancer cells.
For instance, in January 2022, according to the American Cancer Society, a US-based volunteer health organization committed to cancer, in 2022, there were 1,918,030 new cancer cases and 609,360 cancer deaths projected.Whereas in 2020, there were 1,806,590 new cancer cases and 606,520 cancer deaths projected.
Therefore, the rise in cancer patients will drive the tumor infiltrated lymphocyte market.
Technological advancements are a key trend in gaining popularity in the tumor infiltrating lymphocytes market.Major companies operating in the tumor-infiltrating lymphocytes market are focused on developing technologically advanced solutions to strengthen their position in the market.
For instance, in May 2022, Obsidian Therapeutics Inc., a US-based biotechnology firm that develops engineered tumor-infiltrating lymphocytes (TIL cells) and gene treatments, announced the release of cytoDRIVE technology. The new technology’s data shows how to precisely regulate the time and level of protein activity using FDA-approved small chemicals. Using powerful cytokines like IL12 to support cell treatments, is a potential technique for treating solid cancers. The findings show that numerous cytokines, including IL12, IL23, IL2, and IFN, may be regulated robustly and reversibly, possibly allowing for their safe usage in adoptive cell therapy applications.
In January 2021, Turnstone Biologics Corporation, a US-based diagnostic biotechnology firm that is pioneering the development of cancer immunotherapies, acquired Myst Therapeutics Inc. for an undisclosed amount. This acquisition provides Turnstone Biologics Corp. with full rights to Myst Therapeutics Inc.’s technology, complete R&D resources, current development partnerships, and a portfolio of tumor-infiltrating lymphocytes (TIL) projects. Myst Therapeutics Inc. is a US-based biotechnology company that focuses on the development of cancer immunotherapies employing tumor-infiltrating lymphocytes (TIL) and the development of novel T-cell therapeutics for solid tumors.
The countries covered in the tumor infiltrating lymphocytes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The tumor infiltrating lymphocytes market research report is one of a series of new reports from.The Business Research Company that provides tumor infiltrating lymphocytes market statistics, including tumor infiltrating lymphocytes industry global market size, regional shares, competitors with a tumor infiltrating lymphocytes market share, detailed tumor infiltrating lymphocytes market segments, market trends and opportunities, and any further data you may need to thrive in the tumor infiltrating lymphocytes industry.
This tumor infiltrating lymphocytes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: https://www.reportlinker.com/p06457557/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
